Research Article

Correlating Quantitative Fecal Immunochemical Test Results with Neoplastic Findings on Colonoscopy in a Population-Based Colorectal Cancer Screening Program: A Prospective Study

Table 2

Fecal immunochemical test performance by test cut-off.

≥10 μg/g
(≥50 ng/mL)
(/%)
≥15 μg/g
(≥75 ng/mL)
(/%)
≥20 μg/g
(≥100 ng/mL)
(/%)
≥40 μg/g
(≥200 ng/mL)
(/%)
≥100 μg/g
(≥500 ng/mL)
(/%)

CRC449 (2.3)409 (3.1)388 (3.8)344 (5.7)242 (8.4)
Missed CRC40 (8.9)61 (13.6)105 (23.4)207 (46.1)
HRA4012 (20.4)3176 (24.4)2712 (26.9)1911 (31.6)1109 (38.4)
Missed HRA836 (20.8)1300 (32.4)2101 (52.4)2903 (72.4)
MLRA1173 (6.0)772 (5.9)584 (5.8)321 (5.3)132 (4.6)
LRA5029 (25.6)3172 (24.4)2359 (23.4)1247 (20.6)474 (16.4)
All neoplasia10663 (54.2)7529 (57.8)6043 (59.9)3823 (63.2)1957 (67.8)
CSPY saved6641 (33.8)9571 (48.7)13615 (69.3)16773 (85.3)
Total results19660130191008960452887

CRC, colorectal cancer; CSPY, colonoscopy; HRA, high-risk adenoma; LRA, low-risk adenoma; MLRA, multiple low-risk adenomas.